Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease [3] - The company's lead drug candidate, CardiolRx™, is an oral solution containing cannabidiol, which is in clinical development for treating heart disease [3] Clinical Development - CardiolRx™ is entering a late-stage Phase III clinical trial named MAVERIC, targeting patients with recurrent pericarditis who are at high risk for recurrence [2] - The MAVERIC Program includes the Phase II MAvERIC-Pilot study, the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial for recurrent pericarditis [4] - The company has also initiated the ARCHER trial, a Phase II study in acute myocarditis, which is a significant cause of heart failure and sudden cardiac death in young adults [4] Market Opportunity - The market for recurrent pericarditis is estimated to be worth $1 billion, presenting a significant opportunity for CardiolRx™ to transform heart disease care [2] - CardiolRx™ is positioned to fill critical gaps in current treatment options, potentially offering a safer, more cost-effective, and disease-modifying solution for patients [2] Regulatory Status - Cardiol Therapeutics has received Investigational New Drug Application authorization from the US FDA to conduct clinical studies for CardiolRx™ in recurrent pericarditis and acute myocarditis [4] - The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis [4] Financial Position - The company is focused on maintaining a strong financial position to support its clinical development programs and upcoming milestones [2]

Company Overview - Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on anti-inflammatory and anti-fibrotic therapies for heart disease [3] - The company's lead drug candidate, CardiolRx™, is an oral solution containing cannabidiol, currently in clinical development for heart disease treatment [3] Clinical Development - CardiolRx™ is entering a late-stage Phase III clinical trial named MAVERIC, targeting patients with recurrent pericarditis who are at high risk for recurrence [2] - The MAVERIC Program includes the Phase II MAvERIC-Pilot study, the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial [4] - The company has also received FDA authorization for clinical studies evaluating CardiolRx™ for recurrent pericarditis and acute myocarditis [4] Market Opportunity - The market for recurrent pericarditis is significant, with CardiolRx™ positioned to fill critical gaps in current treatment options [2] - CardiolRx™ is expected to be safer, more cost-effective, and disease-modifying, potentially improving the standard of care for patients with recurrent pericarditis [2] Financial Position and Milestones - The company is focused on key upcoming milestones related to the clinical trials and market entry of CardiolRx™ [2] - Cardiol Therapeutics is also developing CRD-38, a novel drug formulation for heart failure, which has substantial healthcare cost implications in the U.S. exceeding $30 billion annually [4]

Core Insights - Penny stocks present a high-risk, high-reward investment opportunity, often attracting investors with low prices and potential for significant returns, but they are frequently associated with scams and lack of financial transparency [1][2] Group 1: Vuzix Corp - Vuzix Corp focuses on smart glasses and augmented reality products, particularly for defense and medical applications [4] - The company announced a major contract with a U.S. aerospace and defense company for customized waveguides and launched its Z100 smart glasses for the consumer market [5] - Vuzix reduced its quarterly cash operating expenses by 28% and secured a $10 million equity investment, with an additional $10 million expected [5] - Following positive news, Vuzix experienced a nearly 88% return over five days, reaching a 52-week high [6] Group 2: GeoVax Labs Inc - GeoVax Labs is a clinical-stage biotech firm developing vaccines for COVID-19, HIV, and treatments for solid tumor cancers [7] - The company reported positive Phase 2 trial results for its dual-antigen COVID vaccine candidate, GEO-CM04S1, and received a $400 million BARDA Project NextGen Award [8] - Analysts have given GeoVax a Buy rating with a consensus price target of $14.20, indicating over 400% upside potential from current levels [9] Group 3: Cardiol Therapeutics Inc - Cardiol Therapeutics is developing CardiolRx, which has shown strong results in a Phase 2 study for recurrent pericarditis and is preparing for late-stage clinical trials [10] - The company was added to PRISM Marketview's Emerging Biotech Index, enhancing its profile, although it has lost nearly half its value since June [11] - Cardiol Therapeutics has a current price target of $8.75, with a recent stock price of $1.58 [10]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024November 18, 2024 11:37 AM EST | Source: Cardiol Therapeutics Inc.Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 ...

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing ma ...

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent PericarditisMAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.October 22, 2024 6:30 AM EDT | Source: Cardiol Therapeutics Inc.Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. S ...

Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of ...

● . . Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares October 10, 2024 9:09 AM EDT | Source: Cardiol Therapeutics Inc. Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfu ...